How Celgene Is Positioned Now

What to Expect from Bristol-Myers Squibb's Acquisition of Celgene (Continued from Prior Part) ## Revenue trends In the first nine months of 2018, Celgene’s (CELG) revenues grew ~18% YoY to reach $11.2 billion from $9.5 billion. Wall Street analysts anticipate that Celgene will report net revenues of $15.2 billion in fiscal 2018, which represents ~17.14% YoY growth. Celgene also provided net revenue guidance for fiscal 2018 to ~$15.2 billion. Celgene estimated that its top products Revlimid, Pomalyst, Otezla, and Abraxane will generate net revenues of $9.7 billion, $2.0 billion, $1.6 billion, and $1.0 billion, respectively, in fiscal 2018. ## Earnings trends In the first nine months of 2018, Celgene’s net income declined ~2% to reach $2.97 billion from $3.02 billion. However, in the third quarter, Celgene’s net income grew ~10% to reach $1.1 billion from $988.0 million. Wall Street analysts expect Celgene to generate a net income of $4.2 billion in fiscal 2018, which represents ~43.67% YoY growth. In the first nine months of 2018, Celgene’s diluted EPS grew ~8% to reach $4.02 from $3.72. Celgene provided EPS guidance for fiscal 2018 to be in the range of $5.25 and $5.75. Wall Street analysts estimate that Celgene is expected to report EPS of $5.73 in fiscal 2018, which represents ~57.42% YoY growth. ## Celgene’s portfolio update Celgene is conducting a phase 1/2 EVOLVE trial of JCARH125, which is evaluating the safety and efficacy of the drugs in the treatment of patients with relapsed or refractory multiple myeloma (or RRMM). Celgene in collaboration with bluebird bio (BLUE) is also conducting a phase 1 trial of bb21217 to evaluate the safety and efficacy of the drug in the treatment of RRMM. In the third quarter of 2018, Celgene initiated the phase 3 COMMANDS trial for evaluation of the safety and efficacy parameters of luspatercept in MDS (myelodysplastic syndromes) patients who are erythropoiesis-stimulating agent-naïve, very low, low or at intermediate risk. Continue to Next Part Browse this series on Market Realist: * Part 1 - Bristol-Myers Squibb to Acquire Celgene * Part 3 - How Bristol-Myers Squibb Stands Now * Part 4 - What to Expect from BMY’s Celgene Acquisition